initi op seen spin-off catalyst act
initi coverag share outperform rate price target road
expect come match spin strong posit rebuild portfolio set next stage growth
expect significantli improv balanc sheet spin transfer exchang note leav
debt ad cash split take account target leverag ratio
intent capit think add anoth debt bolster war chest add
current cash post acquisit would leav cash war
chest meanwhil despit stub close gap somewhat longer trade neg enterpris valu
believ share materi undervalu current valu individu asset ex angi
futur opportun creat manag team histor creat signific sharehold valu
similar posit today estim iac stub non-match group angi homeservic asset trade
million enterpris valu pro forma basi reflect detail spin acquisit
trade line expect net cash posit impli valu stub busi
initi neutral swipe yet growth opportun balanc w/ risk
initi coverag share neutral rate price target process fulli
spin own share spin lead meaning chang capit structur match
group absorb exchang rais debt use cash hand issu dividend sharehold
retir share process return match get elimin dual share class vote structur materi
enhanc share liquid float increas strateg flexibl asid spin view match group
market opportun associ risk balanc particularli light premium valuat match seen materi
growth recent year particularli tinder may start face domest market satur increas competit
legal battl increasingli embolden ftc tinder made much progress intern recent year match
look acceler intern penetr across apac think come risk local tendenc
competit harder navig look sign sustain subscrib growth abil monet
subscrib better expect
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
posit top-line data phase sota-empa trial
leverag medicin chemistri knock-out mous vivo screen research platform
creat small molecul drug candid varieti diseas decemb compani announc top-line data
phase sota-empa fourth nine core phase studi sotagliflozin type diabet program sotagliflozin
mg met primari endpoint superior reduct versu placebo week patient
inadequ glycem control dipeptidyl peptidas inhibitor without metformin also achiev
key secondari endpoint noninferior versu empagliflozin reduct baselin week sotagliflozin
well toler compar safeti prior result full result phase sota-empa anticip present
upcom medic confer
top-lin result remain core zynquista/typ diabet studi occur earli
global blood emerg pharmaceut compani develop innov treatment rare hematolog diseas
lead oxbryta voxelotor oral once-daili first-in-class potenti diseas modifi treatment sickl cell
scd collabor decemb global blood announc collabor agreement
op david nierengarten develop commerci novel medicin scd beta thalassemia term
agreement global blood pay syro million up-front estim million preclin research
least three year million option exercis develop regulatori commerci sales-bas
mileston product result collabor global blood syro plan develop new therapi induc
fetal hemoglobin use syross gene control platform syro present preclin data fetal hemoglobin
repressor induc fetal hemoglobin nearli cell note total hemoglobin increas
exce level associ function cure scd
strong posit global blood end million cash includ approxim
million senior secur credit facil addit tranch million avail draw decemb
project cash runway profit in-lin guidanc view near-term financ risk low
oxbryta voxelotor /scd launch decemb
potenti revers merger chondrial therapeut
zafgen clinical-stag biopharmaceut compani use proprietari inhibitor platform develop novel
treatment complex metabol disord decemb zafgen announc entranc potenti merger agreement
chondrial therapeut inc chondrial lead asset clinic develop treatment friedreich
ataxia fa rare inherit mitochondri diseas caus genet defect result low level frataxin
recombin fusion protein intend deliv human fraxtin fa typic present childhood adolesc caus
progress nervou system damag movement problem chondrial estim fa patient
current cure therapi diseas also decemb chondrial announc phase
dose began decemb receiv pediatr diseas design track
design fda top-line result phase anticip agreement term chondrial
stockhold receiv share newli issu zafgen common share privat placement chondrial stockhold
anticip around combin compani current zafgen sharehold anticip around
upon potenti close transact chondrial becom wholly-own subsidiari zafgen combin
publicli trade compani renam inc headquart bala cynwyd pennsylvania
also upon potenti close transact chondrial ceo carol ben-maimon serv presid ceo
inc recal septemb zafgen report low probabl near-term resolut
clinic hold announc plan explor sharehold valu boost strateg altern includ acquisit
merger busi combin in-licens strateg transact
potenti close merger chondrial therapeut inc
note rais pt
reiter outperform rate recent travel manag reinforc posit view
share rais price target head posit bia toward build materi
supplier outlook singl famili start growth surg recent among forecast monitor setup
posit builder supplier like guidanc confer call appear page
note continu view outlook achiev meet manag
review comp strength partli driven unsustain spend rise tide
report comp miss elev buy side expect earn sharpli miss buy side sell side
expect kmx comp solid absolut basi clear elev spend drove part
comp strength inde retail gross profit per unit gpu held gpu declin due partli extend
post-sal warranti period competit sg spike partli due elev advertis time comp
benefit market-wid forc includ favor use car sale environ lower interest rate caf strong
support third-parti lender fact caf averag interest rate deceler bp sequenti third-parti lend
drove half comp growth initi new system vehicl merchandis
on-line better photo taken degre photo booth like also contribut comp growth believ
smaller driver place roll photo booth month moreov line
proprietari data see comp strong omnichannel caf weaken note omnichannel market
comp slightli better market suggest omnichannel key sale driver
factor weigh earn transitori elev stock-bas compens other
cost longer warranti period linger advertis cost declin could relat boost comp
modestli reduc estim accordingli result indic us sustain drive high-singl
digit comp without ad materi cost make poor trade-off see comp low-mid singl digit
hold oper margin normal environ result low-double-digit ep growth growth profil
signific volatil believ fairli valu calendar ep lead us rais price target
reiter neutral rate
share ralli better fuel offset bleak yield guid
wedbush view ultim sizabl number investor short share head day
outlook object bleak wors anticip along line continu disappoint
ccl rel under-perform rais target reflect would appear bottom sentiment
updat target base estim although remain smallest target multipl
afford cruis name due dispar trajectori rel
friday morn report non-gaap ep ex item ahead street estim
ahead estim ahead midpoint guid rang upsid
stem better yield leaner cost although like get overlook favor guidanc
light yield front came better expect ep front
manag initi ep rang versu earn midpoint ahead
consensu estim fall short estim net yield guidanc constant-curr basi
initi declin well short consensu estim estim flattish growth includ
approxim bp headwind associ brand mix lower yield brand grow faster rate
previous contempl addit bp headwind associ ship deliveri delay ncc ex fuel guidanc
year constant currenc basi expect flat line consensu estim flattish growth
softwar turnaround stori could make pivot year
base recent check field custom partner increment posit head
year end note manag recent analyst day provid strong year target ahead street
expect top line target compound-annual-growth-rate recur revenu grow compound-annual-growth-rate
softwar servic target compound-annual-growth-rate hardwar revenu stream strong thu far light
come eu compani maintain belief start steadi state declin
compound-annual-growth-rate next three year see dynam play field increment make us bullish
stori next month softwar model transit kick gear start posit
note manag provid kpi transpar look ahead perpetu licens term licens
subscript street better gaug transform take place opinion softwar piec
busi pois ramp back tid platform plan significantli hire softwar orient
salespeopl push endeavor inject visibl model still wood chop
opinion turn stori around commend job manag team done thu far watch
stori close given belief new kpi could indic stronger busi model street anticip
point view pivot year transit year financi servic hardwar
provid limit modern softwar secur player offer extens authent fraud prevent
solut could major year success compani invest heavili softwar transit
signific invest continu make infrastructure/r help provid cross-sel
opportun opinion especi mobil secur front compani continu expand mobil fraud
prevent offer nutshel believ core fundament market opportun remain rel
healthi runway ahead continu gain confid stori current take wait
see approach head get comfort softwar turnaround thesi maintain neutral
rate rais price target reflect posit dynam recent check field
repres year supercycl rais pt
head holiday year-end put finish touch would character
histor year compani serv launch pad year iphon supercycl year
ago cupertino face major herculean-lik challeng around lag china demand tariff escal horizon
increas competit smartphon trail samsung other key race investor throw
towel name mani street think growth stori rear view mirror defi
skeptic cook finest hour opinion led success battl china growth struggl settl long
stand lawsuit acquir smartphon modem busi catalyz effort develop
bring market trifecta iphon major consum success gate importantli
play game poker tariff china black cloud work picasso-lik fashion look ahead
come recent asia trip believ underli iphon demand remain comfort ahead street/origin
expect million unit line sand hit posit trend
believ iphon front end current supercycl cupertino slate smartphon set
unveil septemb open floodgat iphon upgrad across board street continu
underestim least iphon version launch main event launch septemb
could includ number versions/model although final spec final like till april
time-frame suppli chain investor eagerli await flagship launch importantli initi build
supplier check indic doubl digit increas expect overal unit y/i earli view phone
come next septemb appear robust supplier point believ million unit could
start point smartphon demand roughli million iphon within million instal base
cupertino current window upgrad opportun
supercycl servic lead share higher head increment posit cupertino given
recent posit asia check technology/upgrad around corner belief china pois see renew
growth share gain heel iphon product cycl skeptic continu underestim china
front estim roughli million million iphon window upgrad opportun key
region hear lower price better camera technolog huawei struggl high-end market
help cupertino healthi iphon sale key region despit nois nutshel convict
supercycl horizon reiter outperform rate rais sotp price target
compani cover respect research analyst analyst certifi view express research report
accur reflect research analyst person view subject secur compani part
compens directli indirectli relat specif recommend view contain research report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
decemb
decemb
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
